Please assess the completion status of the following clinical trial:

Trial Title: Safety of Urate Elevation in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic PD with at least two of the cardinal signs of PD (resting tremor, bradykinesia, rigidity)~* Currently not taking or needing any treatment for PD other than an monoamine oxidase-B (MAO-B) inhibitor~* Age 30 or older at the time of PD diagnosis~* Diagnosis of PD made within past 3 years~* Serum urate ≤ 5.8 mg/dL at initial screening~Exclusion Criteria:~* History of kidney stones, gout, stroke, or heart attack~* History of renal disease or certain cardiovascular problems within the past year~* Acidic urine (pH ≤ 5.0), uric acid, or urate crystalluria at screening~* Use of certain medications including co-enzyme Q, creatine, more than 50 IU of vitamin E daily, and more than 300 mg of vitamin C daily. (A standard daily multivitamin is permitted.)~* Use of anti-PD and other medications targeting central nervous system dopamine transmission~* Known unstable medical or psychiatric condition that may compromise participation in the study~* Women who are pregnant or lactating

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [A:] (Type: PLACEBO_COMPARATOR): Placebo to produce no urate elevation
- [B:] (Type: EXPERIMENTAL): Inosine to produce a mild urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
- [C.] (Type: EXPERIMENTAL): Inosine to produce a moderate urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL

Based on this trial design, predict the completion outcome and termination type (if applicable).